New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs Decapeptide-12

PNC-27 vs Decapeptide-12

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Skin & Cosmetic
Decapeptide-12
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
Half-Life
Not well established; estimated minutes to hours
Not applicable (topical)
Admin Route
Intravenous (research), Intraperitoneal (research)
Topical
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
5 ppm (0.0005%) concentration
Frequency
Not established for human use
Twice daily (AM and PM)
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Reduces hyperpigmentation and dark spots
  • Evens skin tone and improves radiance
  • Inhibits post-inflammatory hyperpigmentation
  • Well-tolerated alternative to hydroquinone
  • Effective for melasma and age spots
  • Non-cytotoxic to melanocytes
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Generally very well-tolerated
  • Rare mild irritation or sensitivity in some skin types
  • Results may take several weeks to become visible
Stacks With